DBV Technologies | Key People and Executives
Pierre-Henri Benhamou
Chairman & Chief Executive Officer
Michael J. Goller
Independent Director
Daniel B. Soland
Independent Director
Torbjörn Bjerke
Independent Director
Pierre-Henri Benhamou
Chairman & Chief Executive Officer
Charles Ruban
Chief Operating Officer
Lucia Septién
Chief Medical Officer
Bertrand Dupont
Chief Technology Officer
Hugh A. Sampson
Chief Scientific Officer
Kevin Trapp
Chief Commercial Officer
David S. Schilansky
Deputy Chief Executive Officer
Magali Richard
Chief Strategy Officer
Susanna Mesa
Chief Business Officer
Sébastien Robitaille
Chief Transformation Officer & Deputy CFO
Pascale Ehouarn
Chief Engineering, Manufacturing & Supply Officer
Laurent Martin
Chief Development Officer
Sara Blum Sherman
Senior Director-Investor Relations & Strategy
Joan Schmidt
General Counsel & Executive Vice President
Michael J. Goller
Independent Director
Daniel B. Soland
Independent Director
Torbjørn Bjerke
Independent Director
| Address |
177-181, avenue Pierre Brossolette
Montrouge Ile-de-France 92120
France
|
|
Employees
|
- |
| Website |
http://www.dbv-technologies.com |
| Updated |
07/08/2019 |
| DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. |
